BioGaia UK Limited 13574654 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is the sale of probiotic products in specialised stores. Digita Accounts Production Advanced 6.30.9574.0 true true false true 13574654 2025-01-01 2025-12-31 13574654 2025-12-31 13574654 bus:OrdinaryShareClass1 2025-12-31 13574654 core:CurrentFinancialInstruments 2025-12-31 13574654 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 13574654 core:WithinOneYear 2025-12-31 13574654 core:OfficeEquipment 2025-12-31 13574654 bus:SmallEntities 2025-01-01 2025-12-31 13574654 bus:Audited 2025-01-01 2025-12-31 13574654 bus:FilletedAccounts 2025-01-01 2025-12-31 13574654 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 13574654 bus:RegisteredOffice 2025-01-01 2025-12-31 13574654 bus:CompanySecretary1 2025-01-01 2025-12-31 13574654 bus:Director3 2025-01-01 2025-12-31 13574654 bus:Director4 2025-01-01 2025-12-31 13574654 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 13574654 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 13574654 bus:Agent1 2025-01-01 2025-12-31 13574654 core:OfficeEquipment 2025-01-01 2025-12-31 13574654 core:Share-basedArrangement1 2025-01-01 2025-12-31 13574654 1 2025-01-01 2025-12-31 13574654 countries:EnglandWales 2025-01-01 2025-12-31 13574654 2024-12-31 13574654 core:OfficeEquipment 2024-12-31 13574654 2024-01-01 2024-12-31 13574654 2024-12-31 13574654 bus:OrdinaryShareClass1 2024-12-31 13574654 core:CurrentFinancialInstruments 2024-12-31 13574654 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13574654 core:WithinOneYear 2024-12-31 13574654 core:OfficeEquipment 2024-12-31 13574654 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13574654

BioGaia UK Limited

Filleted Financial Statements

for the Year Ended 31 December 2025

 

BioGaia UK Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 9

 

BioGaia UK Limited

Company Information

Directors

S A Hicks

T P Agnew

Company secretary

Goodwille Limited

Registered office

1 Chapel Street
Warwick
Warwickshire
United Kingdom
CV34 4HL

Auditors

Bourner Bullock Chartered Accountants
114 St Martin's Lane
Covent Garden
London
WC2N 4BE

 

BioGaia UK Limited

(Registration number: 13574654)
Balance Sheet as at 31 December 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

6

2,150

2,738

Current assets

 

Stocks

7

536,439

449,631

Debtors

8

567,368

488,664

Cash at bank and in hand

 

167,947

71,826

 

1,271,754

1,010,121

Creditors: Amounts falling due within one year

9

(891,317)

(725,324)

Net current assets

 

380,437

284,797

Total assets less current liabilities

 

382,587

287,535

Provisions for liabilities

-

(381)

Net assets

 

382,587

287,154

Capital and reserves

 

Called up share capital

11

1

1

Other reserves

214,859

200,000

Retained earnings

167,727

87,153

Shareholders' funds

 

382,587

287,154

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 21 August 2026 and signed on its behalf by:
 

.........................................
S A Hicks
Director

.........................................
T P Agnew
Director

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

1

General information

The Company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
1 Chapel Street
Warwick
Warwickshire
CV34 4HL
United Kingdom

Principal activity

The principal activity of the Company is the sale of probiotic products in specialised stores.

These financial statements were authorised for issue by the Board on 21 August 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The company made a profit in the year and has net current assets. The financial statements have been prepared on a going concern basis.

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

Revenue recognition

BioGaia’s revenues mainly comprise sales of goods. No commitments for BioGaia remain after delivery since BioGaia does not provide customers with any extended guarantees or the option to return. Control is transferred to the customer when the good is placed at the disposal of the purchaser.The transaction price, i.e. the compensation BioGaia expects to receive in exchange for the goods and services is in most cases fixed and therefore easy to determine. Variable compensation occurs in individual cases, often in combination with requirements for minimum levels of sales, which simplifies assessment of the transaction price. Interest income is recognized in profit or loss in the period to which it pertains.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates taxable income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the Company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the new carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

3 years straight line

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

Financial instruments

Classification
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from related parties and investments in non-puttable ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 

Debtors

Basic financial assets, including trade and other debtors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

Trade debtors are amounts due from customers for merchandise sold in the ordinary course of business.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Creditors

Basic financial liabilities, including trade and other creditors, loans from third parties and loans from related parties, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Such instruments are subsequently carried at amortised cost using the effective interest method, less any impairment.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the Company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Other reserves

Other reserves represent capital contributions from the parent company.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the Company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Share based payments

The Company operates an equity-settled, share-based compensation plan, under which the entity receives services from employees as consideration for equity instruments (options) of the entity. The fair value of the employee services received is measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

3

Significant judgements and key sources of estimation uncertainty

Judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates. In the Directors' opinion there are no significant judgements or key sources of estimation uncertainty.

4

Summary audit opinion

Audit report

The Independent Auditor's Report was unqualified.

The name of the Senior Statutory Auditor who signed the audit report on 21 August 2026 was David Wheeler, who signed for and on behalf of Bourner Bullock.

5

Staff numbers

The average number of persons employed by the Company (including directors) during the year, was 4 (2024 - 2).

6

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 January 2025

3,650

3,650

Additions

838

838

At 31 December 2025

4,488

4,488

Depreciation

At 1 January 2025

912

912

Charge for the year

1,426

1,426

At 31 December 2025

2,338

2,338

Carrying amount

At 31 December 2025

2,150

2,150

At 31 December 2024

2,738

2,738

7

Stocks

2025
£

2024
£

Finished goods and goods for resale

536,439

449,631

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

8

Debtors

Note

2025
£

2024
£

Trade debtors

 

398,616

355,190

Amounts owed by Group undertakings and undertakings in which the Company has a participating interest

73,907

55,274

Prepayments

 

55,494

26,289

Other debtors

 

39,351

51,911

 

567,368

488,664

9

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Trade creditors

 

27,411

47,985

Amounts owed to Group undertakings and undertakings in which the Company has a participating interest

691,874

496,116

Taxation and social security

 

120,145

68,638

Accruals and deferred income

 

42,557

110,348

Other creditors

 

9,330

2,237

 

891,317

725,324

 

BioGaia UK Limited

Notes to the Financial Statements for the Year Ended 31 December 2025

10

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2025
£

2024
£

Not later than one year

2,202

1,953

11

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

1

1

1

1

       

12

Dividends

Final dividends paid

2025
£

2024
£

Final dividend of £Nil per each Ordinary shares

-

-

 

 

13

Share-based payments

Biogaia AB (the parent company of Biogaia UK Ltd) operates equity-settled, option plans for certain employees. The options issued under the plans have a three year cliff vesting period and are dependant on performance based non-market vesting conditions.

14

Parent and ultimate parent undertaking

The Company's immediate and ultimate parent is Biogaia AB, incorporated in Sweden.

 The smallest and largest group in which these financial statements are consolidated is Biogaia AB. These financial statements are available upon request from Biogaia AB, Kungsbroplan 3, 112 27 Stockholm, Sweden.